Louvain-la-Neuve, Belgium, 3 May 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and a global leading provider of dosimetry and quality assurance (QA) solutions, today announces the launch of its QUASAR® GRID3D Advantage Image Distortion Analysis System at the European Society for Radiotherapy and Oncology (ESTRO) 2025 Annual Congress in Vienna, Austria.
This advanced product is uniquely designed for facilities requiring precise Magnetic Resonance (MR) distortion analysis for stereotactic planning, ensuring confidence in geometric fidelity for MR images. It combines automated analysis through user-friendly software with a versatile multi-use solution including various frame adapters or frameless options.
MR is increasingly used in radiation therapy due to its ability to provide superior soft tissue contrast without ionizing radiation. In MR-guided radiation therapy, precise imaging is critical for targeting tumors and protecting surrounding healthy tissue. However, MR images can be subject to geometric distortions that may compromise treatment accuracy. Robust QA tools like GRID3D Advantage are essential to ensure image fidelity and improve clinical confidence.
Ian Paddick, Director at Medical Physics Limited, said: “For the first time, the gold standard of measuring image distortion using the Known Target Method is available for the Vantage Frame setup. This represents a huge step forward in our ability to provide comprehensive QA for Gamma Knife® radiosurgery.”
Jean-Marc Bothy, President of IBA Dosimetry, commented: “We understand that MR simulation has become an integral part of radiation therapy workflows, especially for small field cases where millimeters can impact treatment outcomes. As a result, geometric distortion QA is no longer optional but essential. GRID3D Advantage reflects our dedication to providing clinicians and researchers with accurate and precise tools to evaluate MRI 3D geometric distortion.”
***ENDS***
